Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors
Basic & Clinical Pharmacology & Toxicology · 2023
DOI: 10.1111/bcpt.13928 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Feng Deng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasm Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Sigrid Jusélius Foundation, Cancer Foundation Finland.
Abstract (Originalsprache)
Poly ADP‐ribose polymerase (PARP) inhibitors have been approved for the treatment of various cancers. They share a similar mechanism of action but have differences in pharmacokinetic characteristics and potential for drug–drug interactions (DDI). This study evaluated the potential ATP‐binding cassette transporter‐mediated interactions between PARP inhibitors (niraparib, olaparib and rucaparib) and statins (atorvastatin and rosuvastatin). We studied the inhibitory activity of PARP inhibitors on breast cancer resistance protein (BCRP), multidrug resistance‐associated protein 3 (MRP3) and P‐glycoprotein (P‐gp) using vesicular transport assays and determined the concentrations required for 50% inhibition (IC 50 ). Then, we predicted the increase of statin exposure followed by the administration of PARP inhibitors using a mechanistic static model. Rucaparib was the strongest inhibitor of BCRP‐mediated rosuvastatin transport (IC 50 13.7 μM), followed by niraparib (42.6 μM) and olaparib (216 μM). PARP inhibitors did not affect MRP3. While niraparib appeared to inhibit P‐gp, the inhibition showed large variability. The inhibition of intestinal BCRP by rucaparib, niraparib and olaparib was predicted to elevate rosuvastatin exposure by 52%, 37% and 24%, respectively. The interactions between PARP inhibitors and rosuvastatin are probably of minor clinical significance alone, but combined with other predisposing factors, they may increase the risk of rosuvastatin‐associated adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Feng Deng
Förderung
- Academy of Finland
- Sigrid Jusélius Foundation
- Cancer Foundation Finland
- Sigrid Juséliuksen Säätiö
- Syöpäsäätiö
Zitieren
APA
Deng, F., Sistonen, J., Neuvonen, M., & Niemi, M. (2023). Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13928
Vancouver
Deng F, Sistonen J, Neuvonen M, Niemi M. Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13928
BibTeX
@article{Deng2023,
author = {Deng, Feng and Sistonen, Johanna and Neuvonen, Mikko and Niemi, Mikko},
title = {Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
doi = {10.1111/bcpt.13928}
}
EUVIMED